



The MitraClip Asia-Pacific Registry (MARS): Update

A/Prof Yeo Khung Keong, MBBS, FAMS, FACC, FSCAI

National Heart Centre Singapore




National Heart
Centre Singapore
SingHealth



Academic Healthcare Cluster



Singapore
General Hospital



KK Women's and
Children's Hospital



National Cancer
Centre Singapore



National Dental
Centre Singapore



National Heart
Centre Singapore



National
Neuroscience Institute



Singapore National
Eye Centre



Polyclinics
SingHealth



Bright Vision
Hospital



SingHealth

Partner in
Academic Medicine



PATIENTS. AT THE HEART OF ALL WE DO.®

MARS Registry




- Asia-Pacific MitraClip Registry
- Retrospective registry
- Feb 2011- 2014

2011:

3 Australia
1 Singapore
Malaysia

Feb 2013:
Indonesia

Oct 2013:
China



Feb 2012:
1 Singapore

MARS Registry

- 8 centers
- 5 countries (Singapore, Malaysia, Australia, Indonesia, China)
- Clinical, imaging and follow-up data obtained by respective sites

Current Sites

- Australia
 - Sir Charles Gairdner Hospital, Perth
 - St Vincent's Hospital, Sydney
 - Prince Charles Hospital, Brisbane
- Malaysia
 - Institut Jantung Negara
- Singapore
 - National Heart Centre Singapore
 - National University Heart Centre
- Indonesia
 - Medistra Hospital, Jakarta
- China
 - Second Affiliated Hospital, Zhejiang

Patient Selection

- MR $\geq 3+$
- Underwent MitraClip procedure
- Multidisciplinary team approach and guidelines

Efficacy Outcomes

- 1° outcome: MR $\leq 2+$ at 30 days.
- 2° outcomes
 - Acute procedural success
 - NYHA Class
 - Echo parameters
 - QoL scores

Safety Outcomes

- 30-day mortality
- Stroke, MI, Bleeding requiring >1 unit of blood transfusion, septicaemia, non-elective cardiac surgery, renal failure, ventilation for >48 hours and new-onset AF

Echo Parameters

- MR severity
- LVEDD
- LVESD
- LV volumes
- LA diameters and volumes
- Right heart parameters

Common Data Collection Forms

MARS Clinical Data Form 25 Mar 2013

Hospital: _____

Patient ID: _____

MitraClip Data Collection Form

Date Of Birth: / /
 (dd / mm / yy)

Gender: Male Female

Race: Chinese Malay Indian Eurasian
 Others: _____

Date Of Admission: / /
 (dd / mm / yy)

Date Of Admission: / /
 (dd / mm / yy)

Weight: Kg

Height: cm

Past Medical History

Diabetes Mellitus: Yes No UKN

If yes, Diet control Medical Therapy Insulin Requiring

Smoker: Smoker Non-smoker Ex-smoker- since: _____

Hypertension: Yes No UKN

Congestive Heart Failure: Yes No UKN
 If yes, no of admissions in last 1 year: _____

Peripheral Vascular Disease: Yes No UKN

Dialysis: Yes No UKN

Chronic Pulmonary Disease: Yes No UKN

Hyperlipidemia: Yes No UKN

Atrial Fibrillation: Yes No UKN

Chronic Lung disease: Yes No UKN

History Of Valve Operation: Yes No If yes, please specify: _____

Prior CVA: Yes No UKN

Prior CAD: Yes No UKN

Prior PCI: Yes No UKN

Prior CABG: Yes No UKN

Prior MI: Yes No UKN

MARS Clinical Data Form 25 Mar 2013

Hospital: _____

Patient ID: _____

Clinical Presentation

Baseline NYHA Class: I II III IV

Initial SBP: / / mmHg

Logistic Euro SCORE: _____ %

Euro SCORE II: _____ %

STS score: _____

Baseline MLHF: _____

Baseline AQoL-6D: _____

Baseline EQ-5D: _____

Baseline 6 min walk test: _____ m

Laboratory Tests

Creatinine: Done Not Done . mg/dl

Hemoglobin: Done Not Done . g/dl

BNP: Done Not Done . pg/ml

Pre-procedure

Date Of Procedure: / /
 (dd / mm / yy)

Pre-procedure location: Outpatient Floor ICA/HD ICU

Venous access closure method: Manual pressure PerClose Cut-down stitch

Procedure start time (start of transthoracic access): : : (24 hour clock)

Time septum crossed (end of transthoracic access): : : (24 hour clock)

Clip procedure start time (time of Guide Catheter placement): : : (24 hour clock)

Clip Procedure end time: (Guide removal from femoral vein) : : (24 hour clock)

Total Fluoroscopy Duration: : : (minutes)

Blood products required:

Type and number of units in ml:

Common Data Collection Forms

MARS Echo Form 25 Mar 2013

Hospital: _____

Patient ID: _____

Baseline TTE

Date: _____

MV and LV Parameters	
Mitral Regurgitation Severity (1+,2+,3+,4+)	
Vena Contracta width (cm)	
MR Volume (ml)	
MR fraction	
MR orifice area (cm ²)	
Mitral valve MPG (mmHg)	
Mitral valve orifice area (cm ²)	
Mitral Annular Calcifications (Nil, Mild, Moderate, Severe)	
Mitral Annulus Diameter (cm)	
LVEF (%)	
LV End Diastolic Diameter (cm)	
LV End Systolic Diameter (cm)	
LV End Diastolic Volume (indexed) (ml/m ²)	
LV End Systolic Volume(indexed) (ml/m ²)	
LA Major (cm)	
LA Minor (cm)	
LA volume (indexed) (ml/m ²)	

Other Parameters	
Aortic Valve Area (cm ²)	
Aortic Valve mean gradient (mmHg)	
Aortic Regurgitation (1+,2+,3+,4+)	
Tricuspid Regurgitation (1+,2+,3+,4+)	
PASP (mmHg)	
TR Peak Velocity (m/s)	
TAPSE (cm)	
RA Major (cm)	
RA Minor (cm)	
RV End Diastolic Diameter (cm) (at base)	
RV End Diastolic Diameter (cm) (at mid)	
RV End Diastolic length (cm)	
Tricuspid annulus diameter (cm)	
Degenerative TR (yes/no)	
Functional TR (yes/no)	

MARS Echo Form 25 Mar 2013

Hospital: _____

Patient ID: _____

Baseline TEE

Date: _____

Parameters	
Mitral Regurgitation Severity (1+,2+,3+,4+)	
Vena Contracta width (cm)	
MR Volume (ml)	
MR fraction	
MR orifice area (cm ²)	
Mitral valve MPG (mmHg)	
Mitral valve orifice area (cm ²)	

Functional MR	
MV coaptation depth (cm)	
MV coaptation length (cm)	

Degenerative MR	
Prolapse (Nil, Ant, Post, Bi-leaflet)	
Barlow's present (yes/no)	
Flail (Nil, Ant, Post, Bi-leaflet)	
Flail Gap (cm)	
Flail Width (cm)	

Type of MR: Functional (Ischemic) Functional (Non Ischemic) Degenerative
(Check more than one if more apply)

Immediate Post Procedure TEE

Date: _____

Parameters	
Mitral Regurgitation Severity (1+,2+,3+,4+)	
Mitral valve MPG (mmHg)	


Study Population

- 159 patients recruited
 - 156 with MitraClip deployed
 - 3 excluded (1 Chiari network, 1 inability to grasp leaflet, 1 fractured actuator knob)
- Singapore (2 centres, n=69), Australia (3 centres, n=49), Malaysia (n=23), Indonesia (n=9), China (n=6)

Baseline Characteristics


Patients (n=156)	
Age, yr (SD)	71 (12)
Male	103 (66%)
BMI (SD)	24.7 (4.7)
DM	46 (30%)
Hypertension	98 (63%)
Hyperlipidemia	87 (56%)
COPD	18 (12%)
Prev CVA	19 (12%)
IHD	96 (62%)

Type of MR



Functional Status

NYHA Class




- 6MWT (n=94)
- $303 \pm 147\text{m}$

Procedural Results

- Acute procedural success
 - 93.6% (146/156)
 - 6 SLA, 1 torn chord, 1 difficulty grasping leaflet, 1 MR 3+
- 49.3% (n=77) one clip
- 46.2% (n=72) two clips
- 4.5% (n=7) three clips
- Procedural Time: $130 \pm 98\text{min}$
- Hospital stay: $6.5 \pm 8.4\text{days}$

Primary Efficacy Outcome


- 30-d MR $\leq 2+$
 - 76.9 % (120/156)



Echocardiographic parameters

	Baseline	30-d	n	p value
LVEDD (SD)	6.0 (1.0)	5.7 (1.1)	139	<0.001
LVESD(SD)	4.5 (1.2)	4.3 (1.3)	134	<0.001
LVEF (SD)	47 (16)	46 (17)	134	0.048
PASP (SD)	45 (20)	41 (16)	136	0.011

30-d NYHA Class



- 82.7% NYHA I-II at 30days vs 29.5% at baseline
($p<0.001$)

Primary Safety Outcomes

- 30-d mortality rate
 - 5.8% (n=9)
- 30-d MACE rate
 - 12.8% (n=20)
 - 1 MV surgery, 5 blood transfusion, 2 sepsis, 1 prolonged intubation, 2 heart failure admissions

Conclusion

- Early experience
- Learning curve
- MitraClip is a safe and efficacious therapy in MR patients in the Asia-Pacific

MARS: Site PIs

- Australia
 - Eric Yamen, Sir Charles Gairdner, Perth
 - David Muller, St Vincent's Hospital, Sydney
 - Darren Walters, Prince Charles Hospital, Brisbane
- Malaysia
 - Nasir Muda, Institut Jantung Negara
- Singapore
 - KK Yeo, National Heart Centre Singapore
 - Edgar Tay, National University Heart Centre
- Indonesia
 - Teguh Santoso, Medistra Hospital, Jakarta
- China
 - Xianbao Liu, Second Affiliated Hospital, Zhejiang

Publications: EuroInterventions

Percutaneous mitral valve repair with the MitraClip: early results from the MitraClip Asia-Pacific Registry (MARS)

Khung Keong Yeo^{1,2*}, MBBS; Jonathan Yap¹, MBBS; Eric Yamen³, MD; Nasir Muda⁴, MBBS; Edgar Tay⁵, MBBS; Darren L. Walters⁶, MD; Teguh Santoso⁷, MBBS; Xianbao Liu⁸, MD; Paul Jansz¹⁰, MD; James Yip⁵, MBBS; Robaayah Zambahari⁴, MBBS; Jurgen Passage⁶, MD; Tian Hai Koh¹, MBBS; Jian'an Wang⁸, MD; Gregory Scalia¹¹, MD; Ivandito Kuntjoro³, MBBS; Amiliana M. Soesanto¹², MBBS; David Muller⁹, MD

*1. Department of Cardiology, National Heart Centre Singapore, Singapore; 2. Duke-NUS Graduate Medical School, Singapore;
3. Department of Cardiology, Sir Charles Gairdner Hospital, Perth, Australia; 4. Department of Cardiology, Institut Jantung Negara, Kuala Lumpur, Malaysia; 5. Department of Cardiology, National University Heart Centre, Singapore; 6. Department of Cardiology, Prince Charles Hospital, Brisbane, Australia; 7. Medistra Hospital, Jakarta, Indonesia; 8. Department of Cardiology, Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang, China; 9. Department of Cardiology, St Vincent's Hospital, Sydney, Australia; 10. Department of Cardiothoracic Surgery, St Vincent's Hospital, Sydney, Australia; 11. Department of Cardiothoracic Surgery, Sir Charles Gairdner Hospital, Perth, Australia; 12. Department of Cardiology, National Cardiovascular Center Harapan Kita, Jakarta, Indonesia*

Future plans

- Rotating 1st authorship
- Establishment of echocardiography Core-lab
- Addition of further sites: Australia, New Zealand, Indonesia, Malaysia, China, Brunei, Korea, Japan, Hong Kong, India
- Bodes well for regional collaboration